This poster outlines the study design and rationale description of the phase 3 clinical QWINT program of once-weekly basal insulin efsitora alfa. This program was developed to investigate efficacy and safety of efsitora versus active once-daily basal insulins. The program includes individuals with type 1 and type 2 diabetes. The primary objective for each trial is to compare the change in HbA1c from baseline between efsitora and the active comparator.
